Europe Microbiology Testing/Clinical Microbiology Market was worth USD 1.09 million in 2018 and is projected to be growing at a CAGR of 12.20%, to touch USD 1.93 billion by 2023. Medical microbiology is a branch of medical science concerned with the prevention, diagnosis and treatment of infectious diseases. In addition, this field of science studies various clinical applications of microbes for the improvement of health.
Medical microbiologists often serve as consultants for physicians, providing identification of pathogens and proposing treatment options. Other tasks may include the identification of potential health hazards to the community or observing the evolution of potentially virulent or resistant strains of microbes, educating the community and assisting in the design of health practices.
The growth of the Europe Microbiology Testing/Clinical Microbiology Market is mainly driven by factors such as technological advancements, increasing incidence of infectious diseases and rising outburst of epidemics; growing healthcare spending across the world; and growing funding, research grants, and public-private investments. Furthermore, refining healthcare infrastructure across the developing markets and growing market demand for advanced molecular diagnostic products provide opportunities for players in the clinical microbiology market. Operative barriers for diagnostic test usage and bundled sales by market giants across major markets are the key challenge restraining the growth of the Europe clinical microbiology market.
The Europe Microbiology Testing/Clinical Microbiology Market is segmented on the basis of Application, Clinical Application, Product, and Geography. Based on Product, the Microbiology Testing/Clinical Microbiology market is divided into Pharmaceutical, Clinical, Manufacturing and Energy. The Clinical Application or Disease Area segment consists of Respiratory Diseases, STD and UTI. The Microbiology Testing/Clinical Microbiology Product segment is categorised into Instruments, Analyzers, and Consumables.
The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy. Europe holds the second position in terms of market share globally. There is potential for market growth due to the presence of some untapped markets coupled with the rising frequency of chronic ailments. Increasing private sector investments by key companies to increase R&D to expand market margins in the region are set to further set to augment market growth in the European region.
The significant players in the Europe Microbiology Testing/Clinical Microbiology Market are Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Cepheid (U.S.) Abbott Laboratories Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), and Hologic, Inc. (U.S.), among others.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Instruments
5.1.2.1 Laboratory Instruments
5.1.2.2 Microbiology Analyzers
5.1.3 Reagents
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Pharmaceutical
5.2.3 Clinical
5.2.4 Food Testing
5.2.5 Energy
5.2.6 Chemical and Material Manufacturing
5.2.7 Environmental
5.2.8 Y-o-Y Growth Analysis, By Application
5.2.9 Market Attractiveness Analysis, By Application
5.2.10 Market Share Analysis, By Application
5.3 Disease Area
5.3.1 Introduction
5.3.2 Respiratory Disseases
5.3.3 Bloodstream Infections
5.3.4 Gastrointestinal Diseases
5.3.5 Sexually Transmitted Diseases
5.3.6 Urinary Tract Infections
5.3.7 Periodontal Diseases
5.3.8 Others
5.3.9 Y-o-Y Growth Analysis, By Disease Area
5.3.10 Market Attractiveness Analysis, By Disease Area
5.3.11 Market Share Analysis, By Disease Area
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Application
6.1.3.4 By Disease Area
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Application
6.1.4.4 By Disease Area
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Application
6.1.5.4 By Disease Area
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Biomerieux S.A.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Danaher Corporation
8.3 Becton, Dickinson and Company
8.4 Cepheid (U.S.)
8.5 Abbott Laboratories, Inc.
8.6 Alere, Inc.
8.7 Bio-Rad Laboratories Inc
8.8 F. Hoffman-LA Roche Ltd.
8.9 Hologic Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
